Bicocca Open Archive

Logo unimib boa
CAIROLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 16.438
NA - Nord America 13.657
EU - Europa 7.843
SA - Sud America 2.174
Continente sconosciuto - Info sul continente non disponibili 1.041
AF - Africa 323
OC - Oceania 29
Totale 41.505
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.135
SG - Singapore 5.849
CN - Cina 3.275
IT - Italia 3.078
HK - Hong Kong 2.884
RU - Federazione Russa 1.888
BR - Brasile 1.704
VN - Vietnam 1.577
IE - Irlanda 899
KR - Corea 762
BD - Bangladesh 546
FR - Francia 383
DE - Germania 357
IN - India 347
GB - Regno Unito 284
ID - Indonesia 258
CA - Canada 237
SE - Svezia 200
FI - Finlandia 172
AR - Argentina 167
IQ - Iraq 148
TR - Turchia 120
NL - Olanda 118
MX - Messico 111
PK - Pakistan 103
ZA - Sudafrica 100
AT - Austria 87
EC - Ecuador 86
UA - Ucraina 84
PH - Filippine 77
ES - Italia 76
SA - Arabia Saudita 72
JP - Giappone 68
CO - Colombia 60
UZ - Uzbekistan 51
VE - Venezuela 51
MA - Marocco 45
JM - Giamaica 39
TN - Tunisia 37
CR - Costa Rica 36
MY - Malesia 36
CH - Svizzera 31
CL - Cile 31
EG - Egitto 31
JO - Giordania 31
KE - Kenya 31
PL - Polonia 31
AU - Australia 26
PE - Perù 24
PY - Paraguay 24
NP - Nepal 23
AZ - Azerbaigian 20
ET - Etiopia 20
KZ - Kazakistan 19
LB - Libano 19
TT - Trinidad e Tobago 19
AE - Emirati Arabi Uniti 17
TH - Thailandia 17
TW - Taiwan 17
DZ - Algeria 15
BE - Belgio 14
IR - Iran 14
LT - Lituania 14
OM - Oman 14
AL - Albania 13
NI - Nicaragua 13
HN - Honduras 12
IL - Israele 12
CZ - Repubblica Ceca 11
DK - Danimarca 11
DO - Repubblica Dominicana 11
BO - Bolivia 10
GE - Georgia 10
GR - Grecia 10
GT - Guatemala 10
PS - Palestinian Territory 10
RO - Romania 10
EE - Estonia 9
HR - Croazia 9
HU - Ungheria 9
PT - Portogallo 9
UY - Uruguay 9
AO - Angola 8
PA - Panama 8
BH - Bahrain 7
LY - Libia 7
SV - El Salvador 7
BG - Bulgaria 6
NO - Norvegia 6
SY - Repubblica araba siriana 6
BB - Barbados 5
BY - Bielorussia 5
KW - Kuwait 5
PR - Porto Rico 5
RS - Serbia 5
SN - Senegal 5
GY - Guiana 4
KG - Kirghizistan 4
QA - Qatar 4
SC - Seychelles 4
Totale 40.398
Salva come PNG Salva come JPEG
Città #
Singapore 3.231
Hong Kong 2.868
San Jose 1.688
Ashburn 1.574
Hefei 1.391
Milan 987
Dublin 849
Seoul 746
New York 570
Council Bluffs 561
Santa Clara 546
Ho Chi Minh City 485
The Dalles 462
Chicago 456
Hanoi 394
Los Angeles 343
Dallas 293
Lauterbourg 281
Rome 281
Buffalo 230
Beijing 198
Moscow 195
Jakarta 183
São Paulo 182
Boardman 159
Turin 139
Ann Arbor 126
Phoenix 120
Helsinki 119
Frankfurt am Main 116
Nuremberg 114
Seattle 95
Biloxi 94
Toronto 85
Shanghai 75
Haiphong 69
Figino 68
Atlanta 62
Houston 62
Da Nang 59
Baghdad 56
Philadelphia 55
London 51
Rio de Janeiro 51
Naples 47
Salt Lake City 47
Fairfield 46
Lahore 46
Washington 46
Montreal 44
Desio 43
Tampa 43
Tokyo 43
Brooklyn 42
Chandler 42
Orem 42
Tashkent 41
Amsterdam 39
Bologna 38
Vienna 38
Boston 36
Johannesburg 36
Munich 36
Brasília 35
Dhaka 35
Mumbai 35
Wilmington 35
Bar Harbor 33
Belo Horizonte 33
Biên Hòa 33
Columbus 33
Miami 32
Guangzhou 31
San José 31
Amman 30
Curitiba 30
Porto Alegre 30
Chennai 29
Jacksonville 29
Lappeenranta 29
Palermo 29
Charlotte 28
Las Vegas 28
Riyadh 27
San Francisco 27
Genoa 26
Ha Long 26
Istanbul 26
Newark 26
Quito 26
Denver 25
Nairobi 25
New Delhi 25
Bengaluru 24
Florence 24
Jeddah 24
Manchester 24
Warsaw 24
Can Tho 23
Kingston 23
Totale 22.617
Salva come PNG Salva come JPEG
Nome #
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 496
Assessing eligibility for treatment in acute myeloid leukemia in 2023 402
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 382
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 299
Lymphoma’s last therapeutic option: Freeze it! 295
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 292
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 291
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 285
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 262
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience 262
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 253
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 246
Impact of serial echocardiography in the management of primary cardiac lymphoma 242
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 234
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial 232
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 229
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection 225
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 225
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy 224
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study 224
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome 222
Fasting and Diet: Overview in Chronic Lymphocytic Leukemia 214
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 211
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 208
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 204
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda 198
Impaired survival of patients with non donor-specific anti-HLA antibodies before HLA-mismatched allogeneic stem cell transplantation 196
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy 192
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 190
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 187
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 187
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 184
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 180
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial 180
Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects 178
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 177
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma 176
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? 175
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome 174
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 165
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 164
Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia 163
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 163
Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods 163
A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting 158
Cordycepin (3′dA) Induces Cell Death of AC133+ Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC 158
Myeloma’s multiple morphologies 156
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 156
Hypoplasia of the Spleen: Rare and Puzzling 155
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 153
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 152
In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation 152
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 152
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 151
Duvelisib for the treatment of chronic lymphocytic leukemia 149
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 146
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 145
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 145
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 145
Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol 145
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 144
Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the “Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare” (GITMO) 144
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 144
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 144
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma 143
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial 142
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma 141
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 141
Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy 141
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 141
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 140
Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols? 140
New Insights from CAR-T: An Economic and Organizational Perspective 139
Ibrutinib as bridge therapy to allogeneic stem cell transplantation in refractory mantle cell lymphoma (MCL): A case report 137
Detection of c-KIT antigen (CD117) and c-kit mRNA in acute leukemia 137
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 trial 136
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 136
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 136
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 135
SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents? 135
Feasiblity of autologous stem cell transplantation (ASCT) in chronic lymphocytic leukemia (CLL) patients treated with sequential fludarabine and Campath-1H 133
c-kit activating mutations and mast cell proliferation in human leukemia [4] 133
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 132
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia 132
MIS-A: Beware of non-lymphoma 132
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H 132
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 131
Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia 131
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 131
Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data 130
Multidimensional Results and Reflections on CAR-T: The Italian Evidence 129
Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results 129
Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles 128
VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL 128
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 127
Prognostic impact of immunohistochemical p53 expression in bone marrow biopsy in higher risk MDS: A pilot study 127
Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia 127
C-kit mutations in core binding factor leukemias 127
The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma 127
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL) 126
Totale 17.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 161.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 161.296
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202297 0 0 0 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.794 57 115 139 106 515 840 653 200 657 104 76 332
2024/20259.731 545 1.184 457 439 783 295 687 221 844 1.048 1.035 2.193
2025/202620.253 2.037 2.311 1.568 2.487 1.507 934 2.639 904 1.528 1.438 774 2.126
2026/20275.838 740 935 2.298 1.865 0 0 0 0 0 0 0 0
Totale 41.505